

Amendment Statement of Principles

concerning

MALIGNANT NEOPLASM OF THE EYE (Reasonable Hypothesis)

(No. 19 of 2020)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 28 February 2020

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

Professor Nicholas Saunders AO Chairperson

Contents

1	Name	3
2	Commencement	3
3	Authority	3
4	Amendment	3

1 Name

This is the Amendment Statement of Principles concerning *malignant neoplasm of the eye (Reasonable Hypothesis)* (No. 19 of 2020).

2 Commencement

This instrument commences on 23 March 2020.

3 Authority

This instrument is made under subsections 196B(2) and (8) of the Veterans' *Entitlements Act 1986*.

4 Amendment

The Statement of Principles concerning *malignant neoplasm of the eye* (*Reasonable Hypothesis*) (No. 27 of 2018) (Federal Register of Legislation No. F2018L00196) is amended in the following manner:

Section	Amendment
9(4)	Replace the existing factor in subsection 9(4) with the following:
	being treated with an immunosuppressive drug:
	 (a) for a cumulative period of at least three months before the clinical onset of malignant neoplasm of the eye; and (b) where the first treatment occurred at least five years
	before the clinical onset of malignant neoplasm of the eye; and
	 (c) where that exposure has ceased, the clinical onset of malignant neoplasm of the eye has occurred within ten years of cessation;
	Note: <i>immunosuppressive drug</i> is defined in the Schedule 1 - Dictionary.
Schedule 1 – Dictionary	<i>Replace the existing definition of "immunosuppressive drug" with the following:</i>
	<i>immunosuppressive drug</i> means a drug or an agent which results in substantial suppression of immune responses.
	 Note: Examples of an immunosuppressive drug include, but are not limited to: (a) chemotherapeutic agents used for the treatment of cancer; (b) corticosteroids, other than inhaled or topical corticosteroids; (c) drugs used to prevent transplant rejection; and (d) tumour necrosis factor-α inhibitors.